• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在ABO血型不相容肾移植因特定原因活检中,肾小管周围毛细血管C4d表达与微血管炎症并发的意义。

Significance of C4d expression in peritubular capillaries concurrent with microvascular inflammation in for-cause biopsies of ABO-incompatible renal allografts.

作者信息

Cho Haeyon, Baek Chung Hee, Park Su-Kil, Kim Hyosang, Go Heounjeong

机构信息

Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

Division of Nephrology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

出版信息

Kidney Res Clin Pract. 2024 Jan;43(1):82-92. doi: 10.23876/j.krcp.22.221. Epub 2023 May 12.

DOI:10.23876/j.krcp.22.221
PMID:37448281
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10846988/
Abstract

BACKGROUND

Pathologic diagnosis of antibody-mediated rejection (ABMR) in ABO-incompatible (ABOi) transplantation patients is often challenging because patients without ABMR are frequently immunopositive for C4d. The aim of this study was to determine whether C4d positivity with microvascular inflammation (MVI), in the absence of any detectable donor-specific antibodies (DSAs) in ABOi patients, could be considered as ABMR.

METHODS

A retrospective study of 214 for-cause biopsies from 126 ABOi kidney transplantation patients was performed. Patients with MVI score of ≥2 and glomerulitis score of ≥1 (n = 62) were divided into three groups: the absolute ABMR group (DSA-positive, C4d-positive or C4d-negative; n = 36), the C4d-positive group (DSA-negative, C4d-positive; n = 22), and the C4d-negative group (DSA-negative, C4d-negative; n = 4). The Banff scores, estimated glomerular filtration rates (eGFRs), and graft failure rates were compared among groups.

RESULTS

C4d-positive biopsies showed higher glomerulitis, peritubular capillaritis, and MVI scores compared with C4d-negative specimens. The C4d-positive group did not show significant differences in eGFRs and graft survival compared with the absolute ABMR group.

CONCLUSION

The results indicate that C4d positivity, MVI score of ≥2, and glomerulitis score of ≥1 in ABOi allograft biopsies may be categorized and treated as ABMR cases.

摘要

背景

在ABO血型不相容(ABOi)移植患者中,抗体介导的排斥反应(ABMR)的病理诊断通常具有挑战性,因为没有ABMR的患者C4d常常呈免疫阳性。本研究的目的是确定在ABOi患者中,在没有任何可检测到的供者特异性抗体(DSA)的情况下,C4d阳性伴微血管炎症(MVI)是否可被视为ABMR。

方法

对126例ABOi肾移植患者的214份因病因进行的活检进行回顾性研究。MVI评分≥2且肾小球炎评分≥1的患者(n = 62)被分为三组:绝对ABMR组(DSA阳性,C4d阳性或C4d阴性;n = 36),C4d阳性组(DSA阴性,C4d阳性;n = 22),以及C4d阴性组(DSA阴性,C4d阴性;n = 4)。比较各组的Banff评分、估计肾小球滤过率(eGFR)和移植失败率。

结果

与C4d阴性标本相比,C4d阳性活检显示更高的肾小球炎、肾小管周围毛细血管炎和MVI评分。与绝对ABMR组相比,C4d阳性组在eGFR和移植存活率方面没有显著差异。

结论

结果表明,ABOi同种异体移植活检中C4d阳性、MVI评分≥2和肾小球炎评分≥1可归类并作为ABMR病例进行治疗。

相似文献

1
Significance of C4d expression in peritubular capillaries concurrent with microvascular inflammation in for-cause biopsies of ABO-incompatible renal allografts.在ABO血型不相容肾移植因特定原因活检中,肾小管周围毛细血管C4d表达与微血管炎症并发的意义。
Kidney Res Clin Pract. 2024 Jan;43(1):82-92. doi: 10.23876/j.krcp.22.221. Epub 2023 May 12.
2
Renal Biopsy and Clinical Outcomes in Patients With ABO-Incompatible Renal Transplant: Experience From a Tertiary Care Hospital.ABO血型不相容肾移植患者的肾活检与临床结局:来自一家三级医疗医院的经验
Exp Clin Transplant. 2021 Jun;19(6):527-533. doi: 10.6002/ect.2021.0010. Epub 2021 May 6.
3
Significance of C4d deposition in antibody-mediated rejection.C4d 沉积在抗体介导的排斥反应中的意义。
Clin Transplant. 2012 Jul;26 Suppl 24:43-8. doi: 10.1111/j.1399-0012.2012.01642.x.
4
Molecular Assessment of C4d-Positive Renal Transplant Biopsies Without Evidence of Rejection.无排斥反应证据的C4d阳性肾移植活检的分子评估
Kidney Int Rep. 2018 Sep 18;4(1):148-158. doi: 10.1016/j.ekir.2018.09.005. eCollection 2019 Jan.
5
Histological picture of antibody-mediated rejection without donor-specific anti-HLA antibodies: Clinical presentation and implications for outcome.抗体介导排斥反应而无供体特异性抗 HLA 抗体的组织学图像:临床表现和对结局的影响。
Am J Transplant. 2019 Mar;19(3):763-780. doi: 10.1111/ajt.15074. Epub 2018 Sep 28.
6
Capillary C4d and Kidney Allograft Outcome in Relation to Morphologic Lesions Suggestive of Antibody-Mediated Rejection.与提示抗体介导排斥反应的形态学病变相关的毛细血管C4d与肾移植结果
Clin J Am Soc Nephrol. 2015 Aug 7;10(8):1435-43. doi: 10.2215/CJN.09901014. Epub 2015 Jun 12.
7
Clinical Significance of Revised Banff Criteria in the Diagnosis of Antibody-Mediated Rejection.修订版班夫标准在抗体介导性排斥反应诊断中的临床意义
Transplant Proc. 2019 Jun;51(5):1488-1490. doi: 10.1016/j.transproceed.2019.03.012. Epub 2019 Apr 30.
8
Organ Preservation Solutions in Transplantation: A Literature Review.移植中的器官保存溶液:文献综述
Exp Clin Transplant. 2021 Jun;19(6):511-521. doi: 10.6002/ect.2020.0506. Epub 2021 Mar 31.
9
The relationship of microvascular inflammation with antibody-mediated rejection in kidney transplantation.肾移植中微血管炎症与抗体介导排斥反应的关系。
Am J Transplant. 2025 Jan;25(1):115-126. doi: 10.1016/j.ajt.2024.07.023. Epub 2024 Jul 30.
10
A Probabilistic Approach to Histologic Diagnosis of Antibody-Mediated Rejection in Kidney Transplant Biopsies.肾移植活检中抗体介导排斥反应组织学诊断的概率方法。
Am J Transplant. 2017 Jan;17(1):129-139. doi: 10.1111/ajt.13934. Epub 2016 Aug 3.

引用本文的文献

1
Enzymatic conversion of human blood group A kidneys to universal blood group O.将人类血型 A 肾脏转化为通用血型 O 的酶促转化。
Nat Commun. 2024 Mar 30;15(1):2795. doi: 10.1038/s41467-024-47131-9.
2
C4d Puzzle in ABO-incompatible kidney transplantation.ABO血型不相容肾移植中的C4d难题
Kidney Res Clin Pract. 2024 Jan;43(1):6-7. doi: 10.23876/j.krcp.23.139. Epub 2023 Jul 20.

本文引用的文献

1
The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell- and antibody-mediated rejection.《2019 年班夫肾脏会议报告(一):T 细胞和抗体介导排斥反应标准的更新和澄清》。
Am J Transplant. 2020 Sep;20(9):2318-2331. doi: 10.1111/ajt.15898. Epub 2020 May 28.
2
Banff 2019 Meeting Report: Molecular diagnostics in solid organ transplantation-Consensus for the Banff Human Organ Transplant (B-HOT) gene panel and open source multicenter validation.Banff 2019 会议报告:实体器官移植中的分子诊断- Banff 人类器官移植 (B-HOT) 基因面板共识和开源多中心验证。
Am J Transplant. 2020 Sep;20(9):2305-2317. doi: 10.1111/ajt.16059. Epub 2020 Jun 27.
3
Clinical significance of isoagglutinin titre with the current desensitization protocol in ABO-incompatible kidney transplantation.
现行脱敏方案中同型凝集素效价对 ABO 血型不合肾移植的临床意义。
Nephrology (Carlton). 2019 Jun;24(6):654-660. doi: 10.1111/nep.13412. Epub 2019 Apr 15.
4
The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials.Banff 2017 年会肾脏报告:慢性活动性 T 细胞介导排斥反应、抗体介导排斥反应的修订诊断标准,以及下一代临床试验综合终点的前景。
Am J Transplant. 2018 Feb;18(2):293-307. doi: 10.1111/ajt.14625. Epub 2018 Jan 21.
5
Clinical outcomes of ABO- and HLA-incompatible kidney transplantation: a nationwide cohort study.ABO 和 HLA 不相容的肾移植的临床结果:一项全国性队列研究。
Transpl Int. 2017 Dec;30(12):1215-1225. doi: 10.1111/tri.12979. Epub 2017 Jul 6.
6
ABO-Incompatible Kidney Transplantation.ABO血型不相容肾移植
Front Immunol. 2017 Mar 6;8:234. doi: 10.3389/fimmu.2017.00234. eCollection 2017.
7
Evaluation of Microvascular Inflammation in ABO-Incompatible Kidney Transplantation.评价 ABO 血型不相容肾移植中的微血管炎症。
Transplantation. 2017 Jun;101(6):1423-1432. doi: 10.1097/TP.0000000000001403.
8
Histological Analysis in ABO-Compatible and ABO-Incompatible Kidney Transplantation by Performance of 3- and 12-Month Protocol Biopsies.通过实施 3 个月和 12 个月协议活检对 ABO 相容和 ABO 不相容肾移植的组织学分析。
Transplantation. 2017 Jun;101(6):1416-1422. doi: 10.1097/TP.0000000000001324.
9
Current progress in ABO-incompatible kidney transplantation.ABO血型不相容肾移植的当前进展。
Kidney Res Clin Pract. 2015 Sep;34(3):170-9. doi: 10.1016/j.krcp.2015.08.005. Epub 2015 Aug 20.
10
Long-term Outcomes of ABO-Incompatible Living Donor Kidney Transplantation: A Comparative Analysis.ABO血型不相容活体供肾移植的长期结局:一项比较分析
Transplant Proc. 2015 Jul-Aug;47(6):1720-6. doi: 10.1016/j.transproceed.2015.05.026.